Both Dexcom systems can be programmed to work with insulin pumps, whereas only the FreeStyle Libre 2 system is compatible ...

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products ...

DexCom, Inc.'s growth is impressive but limited ... them – Dexcom's products are compatible with automated insulin pumps. GLP-1 drugs may not be much use to a Type 1 diabetic – other than ...

and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. In light of the recent options history for DexCom, it ...

Then, the user can make insulin adjustments accordingly, whether it's with an insulin pump or manual injections. Dexcom data ...

Medical device specialist DexCom (NASDAQ: DXCM) has substantially underperformed the market over the trailing-12-month period ...

Dexcom designs and commercializes continuous ... and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.

Key Insights The projected fair value for DexCom is US$123 based on 2 Stage Free Cash Flow to Equity Current share... DexCom (DXCM) doesn't possess the right combination of the two key ingredients ...

Lilly has taken a non-exclusive license to deploy Dexcom’s CGM systems – which include app-based remote monitoring and alarm functions – in pen- and pump-based insulin systems that form the ...

Dexcom (DXCM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on January 13. Analyst Mike Kratky from Leerink Partners maintained a Buy rating on the ...

DexCom (NASDAQ:DXCM) shares popped 6% premarket on Monday after the company set its financial forecast for 2025, projecting adjusted gross profit margin of around 64% – 65% on revenue of $4.60B ...

SAN FRANCISCO—After spending the past year extending its portfolio of continuous glucose monitors to include people who may not have diabetes, Dexcom said it expects to see more than $4.03 ...